Market Insights
The breast biopsy market was estimated at US$ 783 million in 2021 and is expected to grow at a CAGR of 10.86% during 2022-2028 to reach US$ ~1.28 billion in 2028.
Breast biopsies are typically performed only when a worrisome lesion or hard, palpable lump is found during one of these test procedures, generally after mammography or ultrasound. A sample of the questionable tissue is removed during the breast biopsy, and the pathologists then examine the sample. By physical examination, self-examination, or mammography, palpable lumps and abnormalities can be found; however, these methods cannot identify whether the abnormal growth is benign or malignant. Typically, a doctor may recommend a breast biopsy if she notices a lump, thickening, or questionable tissue in the patient's breast during a mammography. Breast biopsy is therefore not the first procedure. The majority of the various biopsy methods are minimally invasive.
The expansion of the Breast Biopsy market is now being driven by the minimally invasive process and the rising prevalence of breast cancer cases worldwide. Strict regulations, social exclusion, and limited access to clinical facilities have all had a substantial negative impact on the global growth of the breast biopsy market. Due to the risk of contracting COVID during the pandemic, potential delays in cancer detection or treatment have to be evaluated against the potential for life-threatening diseases. The main obstacle during the pandemic's early phases was this factor.
The rising research activities drives the growth of the breast biopsy market over the forecast period. A USC-led team of scientists discovered signs in September 2022 that a specialised blood test known as a liquid biopsy may be able to predict whether a patient has breast cancer at an early stage and whether it is likely to reoccur. The normal blood draw from a patient's arm is used to do the high-definition complete liquid biopsies in a doctor's office. Once in the lab, the sample is checked for cancerous growths. Nature's npj Breast Cancer publication has published the study demonstrating the effectiveness of liquid biopsies for early breast cancer detection. The USC Norris Comprehensive Cancer Center, Duke University, Billings Clinic, Epic Sciences, and other institutions collaborated in the project. Thus, such measures create lucrative opportunities for market growth in the near future.
Several investments/guidelines in the market have been directed in recent years, which would boost the overall market. Some of them are:
- New biopsy methods and the approval of new products make minimally invasive surgeries possible. Under ultrasound guidance, a 6mm Bergstrom side-cutting biopsy needle was found to be an effective tool for obtaining sizable amounts of tissue. The development of the breast biopsy market as a whole has been considerably impacted by these new tools and methods. Breast biopsy market growth is mostly attributable to rising breast cancer incidence rates in recent years. In 2018, over 63,960 non-invasive procedures were performed, and over 265,000 cancer susceptibility cases were diagnosed. Such reports are promoting market expansion on a whole.
Segment Analysis
The market is divided based on product type, technology, application, and type. On the basis of product type, the market is further segmented into biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, others. Due to the growing acceptance of image-guided procedures in both developed and developing countries, as well as the introduction of cutting-edge and distinctive designs, the biopsy needles sector is projected to hold a sizable part of the breast biopsy market. Consider the tri-axial needle, which has a cutting needle on the exterior, a pincer needle on the outside, and a sharp stylet within. Healthcare professionals may cut through tissue without squeezing it because to the needle's shape. Despite its unusual shape, the needle is clearly visible with CT and ultrasonography, which are frequently utilised for biopsy guidance.
Based on technology, the breast biopsy market has been divided into image-guided biopsy, liquid biopsy, NGS-based biopsy, PCR-based biopsy, microarray-based biopsy, others. The market, on the basis of image-guided biopsy, is further segmented into mammography-guided stereotactic biopsy, ultrasound-guided biopsy, MRI-guided biopsy, and others. The category of liquid biopsy is anticipated to grow the highest during the forecast period. A revolutionary technique that is broadening the range of oncology diagnosis is liquid biopsy. The significant growth of the market can be attributed to the expanding use of cutting-edge NGS-based assays and droplet digital PCR technology for performing liquid biopsies in the majority of developed countries. To bring new products to market, businesses in the sector are increasing their R&D spending. Thus, ongoing clinical trials and a prospective product pipeline will fuel further market expansion.
The breast biopsy market is broken down geographically into geographies, namely North America, Europe, Asia-Pacific, and the Rest of the World (RoW). The market share is dominated by North America. More than 62% of breast cancer cases in the area were recently diagnosed. The region's market has been expanding generally, thanks in part to the region's developing medical infrastructure and technology. Additionally, the growth of the Breast Biopsy market has been impacted by the rising knowledge of recognising the palpable lumps in the breasts, early identification, and self-examination. Breast biopsy procedures have increased due to the minimally invasive diagnostic and simple methods. Due to the limitations imposed by pandemics, several sophisticated healthcare systems have obtained alternative therapeutic pathways. Endocrine therapy for luminal A cancers has been endorsed by 68% of medical organisations in more than 41 nations.
Key Players
The following are the major players in the breast biopsy market:
- ARGON MEDICAL
- Cianna Medical
- Danaher
- Devicor Medical Products Inc.
- F. Hoffmann-La Roche Ltd
- Hologic Inc.
- Johnson & Johnson Services Inc.
- Medical Technologies LLC
- OncoCyte Corporation
- Siemens, Medtronic
- STERYLAB S.r.l.
- Stryker
- Trivitron Healthcare
- United Medical Systems Inc.
The market for breast biopsy is highly competitive. The market players are highly focused on mergers, expansions, and product approvals, to sustain in this market. Below are a few key developments.
- The Brevera Breast Biopsy System with CorLumina Imaging Technology is the world's first and only breast biopsy solution to combine vacuum-assisted tissue acquisition, real-time imaging verification, and advanced post-biopsy handling in one, integrated system, according to a 2020 announcement from Hologic, Inc., an innovative medical technology company primarily focused on improving women's health.
- Brevera breast biopsy system with CorLumina imaging technology, a ground-breaking real-time breast biopsy and verification system that enhances the patient experience and streamlines the biopsy procedure from start to finish, received a CE Mark in Europe in January 2018 from Hologic, Inc. With real-time imaging that provides useful information at the point of care, the first-of-its-kind Brevera system is made to boost biopsy accuracy and provide physicians the confidence to make educated decisions.
The overall competitive landscape has been affected due to these mergers and acquisitions.
Research Methodology
This strategic assessment report, from Stratview Research, provides a comprehensive analysis that reflects today’s breast biopsy market realities and future market possibilities for the forecast period. The report segments and analyzes the market in the most detailed manner in order to provide a panoramic view of the market. The vital data/information provided in the report can play a crucial role for the market participants as well as investors in the identification of the low-hanging fruits available in the market as well as to formulate the growth strategies to expedite their growth process.
This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.
Report Features
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:
- Market structure: Overview, industry life cycle analysis, supply chain analysis.
- Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis.
- Market trend and forecast analysis.
- Market segment trend and forecast.
- Competitive landscape and dynamics: Market share, Product portfolio, New Product Launches, etc.
- Attractive market segments and associated growth opportunities.
- Emerging trends.
- Strategic growth opportunities for the existing and new players.
- Key success factors.
